Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 12, 2008, Pages 1397-1405

  Mundhenke, Christoph ^a   Weigel, Marion Tina ^a   Sturner, Klarissa Hanja ^a   Roesel, Frank ^a   Meinhold Heerlein, Ivo ^a   Bauerschlag, Dirk O ^a   Schem, Christian ^a   Hilpert, Felix ^a   Jonat, Walter ^a   Maass, Nicolai ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Imatinib Mesylate; In vitro; Ovarian cancer; Targeted therapy

Indexed keywords

ABELSON KINASE; CARBOPLATIN; IMATINIB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STEM CELL FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA, MUCINOUS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARBOPLATIN; CARCINOMA, PAPILLARY; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; OVARIAN NEOPLASMS; PACLITAXEL; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RNA, MESSENGER; RNA, NEOPLASM; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED;

EID: 54949157903     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0408-0     Document Type: Article

References (33)

1. DS Alberts AV Hallum III M Stratton-Custis DJ Garcia M Gleason-Guzman SE Salmon P Santabarbara EJ Niesor S Floret CL Bentzen 2001 Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug Clin Cancer Res 7 1246 1250
2. DS Alberts PY Liu SP Wilczynski A Jang J Moon JH Ward JT Beck M Clouser M Markman 2007 Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211) Int J Gynecol Cancer 17 784 788
3. SM Apte CD Bucana JJ Killion DM Gershenson IJ Fidler 2004 Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines Gynecol Oncol 93 78 86
4. SM Apte D Fan JJ Killion IJ Fidler 2004 Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma Clin Cancer Res 10 897 908
5. E Arimoto-Ishida M Ohmichi S Mabuchi T Takahashi C Ohshima J Hayakawa A Kimura K Takahashi Y Nishio M Sakata H Kurachi K Tasaka Y Murata 2004 Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin Endocrinology 145 2014 2022
6. RE Bristow RS Tomacruz DK Armstrong EL Trimble FJ Montz 2002 Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 1248 1259
7. E Buchdunger T O'Reilly J Wood 2002 Pharmacology of imatinib (STI571) Eur J Cancer 38 Suppl 5 S28 S36
8. RL Coleman RR Broaddus DC Bodurka JK Wolf TW Burke JJ Kavanagh CF Levenback DM Gershenson 2006 Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers Gynecol Oncol 101 126 131
9. DD Dunigan SB Waters TC Owen 1995 Aqueous soluble tetrazolium/formazan MTS as an indicator of NADH- and NADPH-dependent dehydrogenase activity Biotechniques 19 640 649
10. Faivre S, Raymond E, Casiraghi O, Temam S, Berthaud P (2005) Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 23:6271-6273; author reply 6273-6274
11. A Frolov S Chahwan M Ochs JP Arnoletti ZZ Pan O Favorova J Fletcher M von Mehren B Eisenberg AK Godwin 2003 Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors Mol Cancer Ther 2 699 709
12. AN Gordon JT Fleagle D Guthrie DE Parkin ME Gore AJ Lacave 2001 Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 3312 3322
13. M Hartman AM Piliponsky V Temkin F Levi-Schaffer 2001 Human peripheral blood eosinophils express stem cell factor Blood 97 1086 1091
14. L Hu J Hofmann Y Lu GB Mills RB Jaffe 2002 Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models Cancer Res 62 1087 1092
15. A Jemal T Murray E Ward A Samuels RC Tiwari A Ghafoor EJ Feuer MJ Thun 2005 Cancer statistics CA Cancer J Clin 55 10 30
16. Y Kano M Akutsu S Tsunoda H Mano Y Sato Y Honma Y Furukawa 2001 In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents Blood 97 1999 2007
17. GW Krystal S Honsawek J Litz E Buchdunger 2000 The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth Clin Cancer Res 6 3319 3326
18. HR Kubler H van Randenborgh U Treiber S Wutzler C Battistel A Lehmer S Wagenpfeil R Hartung R Paul 2005 In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines Prostate 63 385 394
19. H Lassus H Sihto A Leminen S Nordling H Joensuu NN Nupponen R Butzow 2004 Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma Br J Cancer 91 2048 2055
20. S Mabuchi M Ohmichi A Kimura K Hisamoto J Hayakawa Y Nishio K Adachi K Takahashi E Arimoto-Ishida Y Nakatsuji K Tasaka Y Murata 2002 Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel J Biol Chem 277 33490 33500
21. D Matei DD Chang MH Jeng 2004 Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation Clin Cancer Res 10 681 690
22. D Matei RE Emerson YC Lai LA Baldridge J Rao C Yiannoutsos DD Donner 2006 Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer Oncogene 25 2060 2069
23. JP Neijt SA Engelholm MK Tuxen PG Sorensen M Hansen C Sessa CA de Swart FR Hirsch B Lund HC van Houwelingen 2000 Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer J Clin Oncol 18 3084 3092
24. C Page HJ Lin Y Jin VP Castle G Nunez M Huang J Lin 2000 Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis Anticancer Res 20 407 416
25. Palumbo C, van Roozendaal K, Gillis AJ, van Gurp RH, de Munnik H, Oosterhuis JW, van Zoelen EJ, Looijenga LH (2002) Expression of the PDGF alpha-receptor 1.5 kb transcript, OCT-4, and c-KIT in human normal and malignant tissues. Implications for the early diagnosis of testicular germ cell tumours and for our understanding of regulatory mechanisms. J Pathol 196:467-477
26. K Pietras A Ostman M Sjoquist E Buchdunger RK Reed CH Heldin K Rubin 2001 Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors Cancer Res 61 2929 2934
27. W Remmele HE Stegner 1987 Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue Pathologe 8 138 140
28. C Roche-Lestienne V Soenen-Cornu N Grardel-Duflos JL Lai N Philippe T Facon P Fenaux C Preudhomme 2002 Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment Blood 100 1014 1018
29. K Satomura AR Derubeis NS Fedarko K Ibaraki-O'Connor SA Kuznetsov DW Rowe MF Young P Gehron Robey 1998 Receptor tyrosine kinase expression in human bone marrow stromal cells J Cell Physiol 177 426 438
30. TJ Shaw BC Vanderhyden 2007 AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate Gynecol Oncol 105 122 131
31. JE Thompson CB Thompson 2004 Putting the rap on Akt J Clin Oncol 22 4217 4226
32. JR Westphal R Van't Hullenaar R Peek RW Willems K Crickard U Crickard J Askaa I Clemmensen DJ Ruiter RM De Waal 2000 Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo Int J Cancer 86 768 776
33. ZQ Yuan RI Feldman GE Sussman D Coppola SV Nicosia JQ Cheng 2003 AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance J Biol Chem 278 23432 23440